医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Meiji Seika Pharma Co., Ltd: Support for Control of Novel Coronavirus in China

2020年02月21日 PM03:00
このエントリーをはてなブックマークに追加


 

TOKYO

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan: “Meiji”) announced today that Meiji decided a financial donation to support coronavirus outbreak control in China.

Daikichiro Kobayashi, President and Representative Director said “First of all, we extend our sincerest condolences to the victims and their families. For about 30 years, we have been operating its business in Guangdong and Shandong, and we greatly appreciate the customers and partners all over in China. We would like to give our support to everyone there and hope our donation helps.”

We sincerely pray for early recovery of Novel coronavirus associated pneumonia patients and the end of virus infection in China.

Details of the donation
- Amount of contribution: RMB 1 million (approximately JPY 16 million)
- Donated to: Red Cross Society of China

View source version on businesswire.com: https://www.businesswire.com/news/home/20200220005336/en/

CONTACT

Beijing Office: (010)65388196

Zhao Chengguo

https://www.meiji.com/global/about-us/corporate-profile/meiji-seika-pharma/

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024